CN111388665B - 一种治疗肿瘤的复合物及其制剂和用途 - Google Patents
一种治疗肿瘤的复合物及其制剂和用途 Download PDFInfo
- Publication number
- CN111388665B CN111388665B CN202010213016.6A CN202010213016A CN111388665B CN 111388665 B CN111388665 B CN 111388665B CN 202010213016 A CN202010213016 A CN 202010213016A CN 111388665 B CN111388665 B CN 111388665B
- Authority
- CN
- China
- Prior art keywords
- compound
- antibody
- tumor
- mithramycin
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 title abstract description 37
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims abstract description 23
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims abstract description 23
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 claims abstract description 23
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960003171 plicamycin Drugs 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 12
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 10
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract description 9
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 7
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 235000008207 calcium folinate Nutrition 0.000 description 2
- 239000011687 calcium folinate Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000009104 chemotherapy regimen Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical compound [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 208000033133 Testicular seminomatous germ cell tumor Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- JYEFSHLLTQIXIO-SMNQTINBSA-N folfiri regimen Chemical compound FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 JYEFSHLLTQIXIO-SMNQTINBSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 201000003073 testicular leukemia Diseases 0.000 description 1
- 208000024662 testicular seminoma Diseases 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明提供一种治疗肿瘤的复合物及其制剂和用途，所述复合物包括光辉霉素和PD‑1抗体；所述复合物内光辉霉素和PD‑1抗体具有非常显著的协同作用，两药联用可以用于治疗结肠癌等肿瘤，有效提高对肿瘤的治疗效果，减少患者并发症的发生及发展。
Description
技术领域
本发明属于含有机有效成分的医药配制品领域，特别涉及一种治疗肿瘤的复合物及其制剂和用途。
背景技术
肿瘤是威胁人类健康最重要的疾病之一，其发病率呈逐年上升的趋势。结肠癌是由于结肠粘膜上皮或腺体上失去正常生长机制的恶性细胞不断增殖而产生的恶性肿瘤，好发于直肠与乙状结肠交界处。结肠癌的主要治疗手段包括手术治疗、放化疗等。化疗方案中，国际上公认的标准疗法是5-FU+甲酰四氢叶酸(LV)为基础的化疗方案，经典方案主要包括FOLFOX(奥沙利铂+5-FU+亚叶酸钙)和FOLFIRI(伊立替康+5-FU+亚叶酸钙)方案。
光辉霉素(mithramycin A，MIT)属于抗肿瘤抗生素类药物，曾经广泛用于治疗恶性高钙血症、睾丸精原细胞瘤和白血病等疾病，其在高剂量下虽显示出抗肿瘤的效果，但同时具有严重副作用，因此限制了其在临床上的广泛应用。
PD-1是人体免疫系统T细胞上的一个药物靶点，针对这一靶点设计的药物可以激活T细胞对肿瘤细胞的免疫作用，从而唤醒患者自身的抗肿瘤效应。因此，PD-1抗体药物可用于治疗肿瘤。有数据显示，PD-1抗体能使四分之一至五分之一的非小细胞肺癌患者，黑色素瘤患者，或肾细胞癌患者产生客观反应，显示出良好的临床应用价值。
但是现有技术并没有公开过由光辉霉素和PD-1抗体组成的复合物，也没未公开过该复合物的治疗用途。
发明内容
为了解决现有技术存在的问题，本发明提供一种由光辉霉素和PD-1抗体组成的治疗肿瘤的复合物及其制剂和用途。
本发明其中一个技术方案提供一种治疗肿瘤的复合物，所述复合物包括光辉霉素和PD-1抗体。
其中光辉霉素为低剂量，PD-1抗体为抑瘤率达到20-30％的有效剂量。
进一步改进的方案中，所述光辉霉素和PD-1抗体的质量比为1-10：10-1。
进一步改进的方案中，光辉霉素和PD-1抗体的质量比为2：3。
本发明另一个技术方案提供一种制剂，所述制剂包括复合物和药用载体。
本文中所述“药用载体”是指用于治疗及给药的载体，包括各种赋形剂和稀释剂，并且是本领域普通技术人员所熟知的。
本发明另一个技术方案提供一种所述复合物在制备用于治疗肿瘤的药物中的应用。
进一步改进的方案中，所述肿瘤为结肠癌。
进一步改进的方案中，所述复合物中光辉霉素和PD-1抗体可以先后使用也可以同时使用。
本发明的有益效果在于，本发明提供一种由青光辉霉素和PD-1抗体组成的复合物，复合物内光辉霉素和PD-1抗体具有非常显著的协同作用，两药联用可以用于治疗结肠癌等肿瘤，有效提高对肿瘤的治疗效果，减少患者并发症的发生及发展。
附图说明
图1为本发明提供的复合物对结肠癌MC38小鼠体重的影响；
图2为本发明提供的复合物对结肠癌MC38肿瘤体积的影响；
图3为本发明提供的复合物对结肠癌MC38瘤重的影响。
具体实施例方式
试验例1光辉霉素和PD-1抗体联合的动物试验
运用小鼠结肠癌MC38皮下移植瘤模型评价光辉霉素和PD-1抗体联合的体内疗效。
取MC38细胞，按50×106/0.2mL/只接种于C57BL6小鼠腋窝皮下。第9天将荷瘤鼠按瘤块大小分组，每组5只，使每组动物的瘤块大小平均值接近。实验共分4组，给药方式均为腹腔给药，隔日给药一次，共给药4次。4组分别为：对照组(生理盐水)，给药剂量为0.2mL/只；光辉霉素组(本实验室自制)，给药剂量为2mg/kg；PD-1抗体组(Bioxcell InVivoPlusanti-mouse PD-1)，给药剂量为3mg/kg；光辉霉素和PD-1抗体联合组，同时给予光辉霉素(给药剂量为2mg/kg)和PD-1抗体(给药剂量为3mg/kg)。实验期间每2-3天测量一次肿瘤长径a和短径b，并记录动物体重。各组对小鼠体重的影响结果见图1。以公式V＝1/2ab2计算瘤体积和抑瘤率，抑瘤率(％)＝(对照组瘤体积-实验组瘤体积)/对照组瘤体积×100％，抑瘤率的结果见表1。各组MC38瘤体积的结果见图2；当瘤体积达到1000mm3时为实验终点，处死动物并剥取肿瘤称重，各组MC38瘤重的结果见图3。
计算两药相互作用系数CDI，结果见表1。CDI＝AB/(A×B)。AB为两药联用组与对照组瘤重比值；A或B为各药物单独使用组与对照组瘤重比值。
表1各组的抑瘤率和CDI结果
结果表明，两药联合后的CDI<0.7，因此两药联合的协同作用非常显著。采用光辉霉素和PD-1抗体联合作用于MC38皮下移植瘤模型时，两药体现出明显的协同增效作用。
Claims (1)
1.一种复合物在制备用于治疗结肠癌的药物中的应用，其特征在于，所述复合物由光辉霉素和PD-1抗体组成，所述光辉霉素和PD-1抗体的质量比为2：3。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010213016.6A CN111388665B (zh) | 2020-03-24 | 2020-03-24 | 一种治疗肿瘤的复合物及其制剂和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010213016.6A CN111388665B (zh) | 2020-03-24 | 2020-03-24 | 一种治疗肿瘤的复合物及其制剂和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111388665A CN111388665A (zh) | 2020-07-10 |
| CN111388665B true CN111388665B (zh) | 2022-09-16 |
Family
ID=71416428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010213016.6A Expired - Fee Related CN111388665B (zh) | 2020-03-24 | 2020-03-24 | 一种治疗肿瘤的复合物及其制剂和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111388665B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CN109970857A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
-
2020
- 2020-03-24 CN CN202010213016.6A patent/CN111388665B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| CN109970857A (zh) * | 2017-12-27 | 2019-07-05 | 信达生物制药(苏州)有限公司 | 抗pd-l1抗体及其用途 |
Non-Patent Citations (2)
| Title |
|---|
| A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity;Keshav Karki等;《Molecular Cell Biology》;20200302;第80卷(第5期);第1011-1023页 * |
| Mithramycin suppresses tumor growth by regulating CD47 and PD-L1 expression;Jianhua Gong等;《Biochemical Pharmacology》;20211227;第197卷;第1-13页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111388665A (zh) | 2020-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109985237B (zh) | 一种治疗结直肠癌的药物组合物及其应用 | |
| CN118059108B (zh) | 一种药物组合物及其在制备抗肿瘤药物中的应用 | |
| CN111388665B (zh) | 一种治疗肿瘤的复合物及其制剂和用途 | |
| CN101773499A (zh) | 延胡索乙素的新用途 | |
| CN110664807B (zh) | 一种具有协同抗黑色素瘤功效的药物组合物及其应用 | |
| US20200289527A1 (en) | FORMULATION CONTAINING A-DECARBONIZED-5a ANDROSTANE COMPOUND FOR INCREASING WHITE BLOOD CELL AND USE THEREOF | |
| CN111494385B (zh) | 一种治疗卵巢癌的药物及其制备方法和用途 | |
| CN113440534A (zh) | 一种毛蕊花糖苷在制备药物中的应用 | |
| CN101856359B (zh) | 一种抗急性髓系白血病的药物组合物 | |
| CN111558045A (zh) | 一种治疗肺癌的药物组合物 | |
| CN113663081A (zh) | 千层纸素和pd-1/pd-l1抑制剂在制备肝癌治疗药物中的应用 | |
| CN111939159A (zh) | Nsc 23766辅助肿瘤放射治疗的用途 | |
| CN104688748A (zh) | 一种含有熊果酸和环磷酰胺的药物组合物 | |
| CN111514290A (zh) | 一种葫芦素组合物及其用途 | |
| CN111714500A (zh) | 一种含柚皮素的药物组合物及其在治疗大肠癌上的应用 | |
| CA3135916A1 (en) | Combined use of a-nor-5a androstane compound drug and anticancer drug | |
| CN111728960B (zh) | 富马酸比索洛尔联合多西他赛在制备抗肿瘤药物中的应用 | |
| CN111840523B (zh) | 一种含活性蛋白和活性脂肪酸的抗癌症的药物组合物 | |
| CN109453195B (zh) | 一种用于抑制肿瘤细胞的药物组合物 | |
| CN109966275A (zh) | 醌式查尔酮化合物在制备抗肿瘤药物中的应用 | |
| CN117866069B (zh) | 一种碘-131标记的小分子多肽tfmp-y4及其制备方法和应用 | |
| CN102309493B (zh) | 一种抗癌药物组合物 | |
| CN102716465B (zh) | 治疗肿瘤的药物组合物及其制备方法 | |
| CN105534972B (zh) | 一种治疗乳腺癌的药物组合物及其应用 | |
| CN114010657A (zh) | 卵巢癌细胞在制备治疗胰腺癌药物中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220916 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |